1. Volume 154, Issue 5, Pages 1061-1069 (November 2018)
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS , a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis 
Scott M. Palmer, MD, Laurie Snyder, MD, Jamie L. Todd, MD, Benjamin Soule, MD, Rose Christian, MD, Kevin Anstrom, PhD, Yi Luo, PhD, Robert Gagnon, PhD, Glenn Rosen, MD 
CHEST 
Volume 154, Issue 5, Pages (November 2018)
DOI: /j.chest
Copyright © 2018 The Authors Terms and Conditions

2. Figure 1
Study flow. AE = adverse event; qd = once daily. aA total of 182 screened patients failed screening and were not randomized. bThe study was terminated early, and the last 10 patients were withdrawn after the sponsor's decision to stop the study because of concerns regarding potential gallbladder toxicity noted in three patients.
CHEST  , DOI: ( /j.chest )
Copyright © 2018 The Authors Terms and Conditions

3. Figure 2
Change in FVC from baseline to week 26 (intent-to-treat population). *P < .05 vs placebo as assessed by a linear mixed-model repeated-measures analysis adjusted for age, sex, and height. See Figure 1 legend for expansion of abbreviation.
CHEST  , DOI: ( /j.chest )
Copyright © 2018 The Authors Terms and Conditions

4. Figure 3
A-C, Change in quantitative lung fibrosis (A), dyspnea (B), and lung fibrosis (C) from baseline to week 26 (intent-to-treat population). *From an analysis of variance with age, sex, and height as covariates; the output was backtransformed to obtain results in terms of the ratio of week 26 to baseline. Dlco = diffusing capacity for carbon monoxide. See Figure 1 legend for expansion of other abbreviation.
CHEST  , DOI: ( /j.chest )
Copyright © 2018 The Authors Terms and Conditions

5. Figure 4
Changes in biomarkers of interest related to fibrosis and inflammation. See Figure 1 legend for expansion of abbreviation.
CHEST  , DOI: ( /j.chest )
Copyright © 2018 The Authors Terms and Conditions